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Background: The objective of our study was to assess the cost-effectiveness of ivabradine plus standard care (SoC)
in chronic heart failure (CHF) patients with sinus rhythm and a baseline heart rate≥ 75 b.p.m. in Greece, in comparison
with current SoC alone.
Methods: An existing cost-effectiveness model consisting of two health states, was adapted to the Greek health care
setting. All clinical inputs of the model (i.e. mortality rates, hospitalization rates, NYHA class distribution and utility
values) were estimated from SHIFT trial data. All costing data used in the model reflects the year 2013 (in €). An
incremental cost effectiveness ratio (ICER) per quality-adjusted life year (QALY) gained was calculated. Deterministic and
probabilistic sensitivity analyses (PSA) were conducted. The horizon of analysis was over patient life time and both cost
and outcomes were discounted at 3.5% per year. The analysis was conducted from a Greek third party-payer perspective.
Results: The Markov analysis revealed that the discounted quality-adjusted survival was 4.27 and 3.99 QALYs in
the ivabradine plus SoC and SoC alone treatment arms, respectively. The cumulative lifetime total cost per patient
was €8,665 and €5,873, for ivabradine plus SoC and SoC alone, respectively. The ICER for ivabradine plus SoC versus SoC
alone was estimated as €9,986 per QALY gained. The PSA showed that the likelihood of ivabradine plus SoC
being cost-effective at a threshold of €36,000/QALY was found to be 95%.
Conclusions: Ivabradine plus SoC may be regarded as a cost-effective option for the treatment in CHF patients
in Greece.
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Heart failure (HF) is a major public health concern
worldwide [1]. Almost 1–2% of the population in Euro-
pean countries suffers from HF, with the prevalence ris-
ing to ≥ 10% among the population aged ≥ 70 years [2].
Moreover, HF has a poor prognosis as 40% of patients
die within a year from the diagnosis date but thereafter
the mortality is less than 10% per year [3]. Prognosis and
patient management are correlated to the severity of
heart disease. The main tool used to estimate the heart
disease severity is the New York Heart Association
(NYHA) classification [4]. Moreover, health-related qual-
ity of life (HR-QoL) of HF patients is reduced by the* Correspondence: kurlaba@hua.gr
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unless otherwise stated.physical, social and emotional limitations imposed by the
disease. These symptoms may be caused by the disease it-
self, by co-morbidities, or can result side effects of treat-
ments [5]. In addition to its substantial effect on morbidity
and mortality, HF is one of the most costly chronic dis-
eases in developed countries. Costs associated with HF
constitute 1-2% of all healthcare expenditure [6].
Current treatments aim to relieve and stabilize symptoms
and prolong survival by stopping, stabilizing or reversing
the progression of HF [7]. Standard pharmacological
treatment includes beta-blockers, angiotensin-converting-
enzyme (ACE) inhibitors and/or angiotensin receptors
blockers (ARBs), aldosterone antagonists and diuretics [5].
Ivabradine (Procoralan®) is a new therapeutic option for
patients with chronic heart failure (CHF) in sinus rhythm.
Ivabradine is a pure heart rate lowering agent, and repre-
sents the first in a new class of agents acting by selectiveal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Structure of the model.
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that controls the spontaneous diastolic depolarisation
in the sinus node and regulates heart rate. The cardiac
effects are specific to the sinus node with no effect on
intra-atrial, atrioventricular or intraventricular conduction
times, nor on myocardial contractility or ventricular repo-
larization [8].
The clinical effect of ivabradine plus standard care (SoC)
versus placebo on top of SoC has been evaluated through a
Phase III international, multicentre randomised controlled
trial (SHIFT trial) [9]. The primary endpoint in SHIFT
was a composite of cardiovascular (CV) death or
hospitalization for worsening HF. This study showed
that ivabradine plus SoC was associated with fewer
hospital admissions for worsening HF (first event hazard
ratio (HR): 0.74; 95% Confidence Interval (CI): 0.66-0.83,
p < 0.0001) and lower mortality rates due to HF (HR: 0.74;
95% CI: 0.58-0.94, p = 0.014). Moreover, SHIFT indicated
that ivabradine plus SoC was associated with significantly
fewer serious adverse events [9].
While the use of ivabradine for the treatment of pa-
tients with CHF may be considered to be an effective
option, it may impose additional costs to the third party
payers and society. The recent climate of the major finan-
cial crisis has resulted in strong health care budgetary con-
straints. This imposes the need to use treatments which
are not only clinically effective but also economically effi-
cient, in order to maximize the value for money spent in
health care. Simple cross-therapy and cross-country price
comparisons are misleading and are not sufficient to
determine policies on whether or not (and how) certain
treatments should be used. Total treatment cost should
be considered and weighed up against the health benefit
of a new treatment in relation to existing ones. This need
led to the use of economic assessment of technologies
used in health care delivery, in the context of which the
cost-effectiveness ratio of new treatments is often assessed
in comparison to that of existing alternatives. Clinical
trials rarely collect sufficient data on treatment costs and
consequences for rigorous economic assessment. Thus,
mathematical modeling is required to support decision
making [10].
Therefore, the purpose of the present study was to
conduct an economic evaluation comparing ivabradine
plus SoC versus SoC alone in patients with sinus rhythm
with NYHA class II-IV CHF and a baseline heart rate ≥
75 b.p.m in Greece.
Methods
In the present study, an existing Markov model developed
for the Health Technology Assessment of ivabradine by
National Institute for Health and Care Excellence (NICE),
[11] was adapted to the Greek health care setting. The
model has been based on the results of the SHIFT trial[9], taking a third party-payer perspective. Costs and out-
comes that occur beyond one year are discounted at a
3.5% annual rate, consistent with the NICE recommenda-
tions [12]. As this study is an economic evaluation analysis
and does not involve human subjects no ethics approval
issues arise. Input data including human material or human
data were derived from other published studies performed
with the approval of an appropriate ethics committee.
Model structure
A simple two state Markov cohort model has been used
in the analysis (health states: alive, dead) (Figure 1). Pa-
tients enter the model in the “alive” health state and are
treated with ivabradine plus SoC or SoC alone. Then, in
each subsequent one month cycle during their life span,
patients can either remain alive or die from a CV cause
(HF and non-HF CV cause) or non-CV cause.
Alive patients are subdivided into NYHA classes (I, II,
III and IV) taking into consideration the SHIFT trial data.
The proportion of patients in each NYHA class is mod-
eled to change over time. These NYHA states have been
included to capture the quality of life (QoL) implications
of HF. The rate of hospitalization was also considered in
the model but, as with NYHA class, not as separate health
states. The hospitalization rates were indirectly modeled
to take into account the associated resource use and tran-
sient reductions in QoL. A series of multivariable risk
equations have been used to predict the risk of mortality,
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allocation and a range of patient baseline characteristics
selected on the basis of the SHIFT study protocol, a
previous HF risk equation and clinical advice, as de-
scribed in detail below.
The key assumptions considered in the model are briefly
presented in Table 1 and described below in detail.
Comparators/schedules
In the present analysis, ivabradine plus SoC therapy is
compared to SoC alone. SoC is considered equivalent
across treatment groups. In particular, the SoC drugs
included in the analysis reflect those drugs currently
recommended in ESC guidelines (beta-blockers, ACE




In the base case analysis, CV and non-CV mortality was
considered separately. The risk of CV mortality in patients
who do not receive ivabradine was estimated based on
SHIFT SoC data, by using multivariable risk equations
for both the within-trial (29 months) and post-trialTable 1 Summary of key assumptions considered in the
cost-effectiveness model
Parameter Key assumptions
Model structure Two-stage Markov cohort model
CE model time horizon Lifetime
Model cycle Monthly
CV mortality for SoC SHIFT data by applying Gompertz
survival model
HR for CV mortality of
ivabradine vs SoC
0.90 (0.80 – 1.03) based on SHIFT data
Rate hospitalization SHIFT data by applying Poisson model
Rate ratio for hospitalization
of ivabradine vs SoC
0.83 (0.78 – 0.93) based on SHIFT data
Length of hospitalization Local data (based on experts’ opinion)
Utility data SHIFT data by applying mixed
regression model
NYHA data SHIFT data by applying adjusted
ordered logistic regression
Ivabradine treatment effect Cardiovascular endpoint
Ivabradine use (years) Lifelong
Cost discount rate per annum 3.5%
Effects discount rate per annum 3.5%
Resource utilization and
unit costs
Local data (government gazette and
experts’ opinion)
Outcome mesaures QALYs, LYs, ICER per QALY and per LY
gained, lifetime total cost
CE: cost-effectiveness; HR: hazard ratio; QALYs: quality-adjusted life years; LYs:
life years; ICER: incremental cost effectiveness ratio; CV: cardiovascular; NYHA:
New York Heart Association.extrapolated period. In the base case analysis, the CV
mortality risk for patients who received SoC alone was
estimated by applying a parametric survival regression
model on the mortality data of the full SHIFT cohort.
The Gompertz distribution was found to best fit the ob-
served mortality data based on statistical evidence (AIC
and BIC criteria), a visual review of Kaplan-Meier survival
plots versus predicted curves and the plausibility of pre-
dicted survival in the extrapolated, post-trial period [11].
Survival models based on the exponential and Weibull
parametric distributions, the next best fitting distributions,
and Kaplan Meier data, were included in the model as part
of the sensitivity analysis [11].
The CV mortality risk equation was estimated adjust-
ing for a series of baseline patient characteristics. The
purpose of including these covariates was to generate
different estimates of mortality, depending on the base-
line characteristics of populations. The covariates con-
sidered for the analysis were patient baseline characteristics;
baseline use of heart failure medications; prior use of other
cardiac therapies; medical history: prior event; Patient
biological characteristics.
The treatment effect on CV mortality for ivabradine
plus SoC was estimated by applying a relevant treatment
effect (HR) obtained from the parametric model to the
underlying mortality risk associated with the SoC group.
Specifically, the HR of 0.90 obtained from the Gompertz
model was applied.
A separate sensitivity analysis considering only the
cause-specific HF mortality endpoint was also considered
(with non-HF CV death modeled equivalent to SoC) [11].
The non-CV mortality rate was modeled to be equiva-
lent for ivabradine plus SoC and SoC alone. This rate was
estimated by using the age and sex adjusted Greek mortal-
ity rates based on the latest data of National Statistics
Service (www.statistics.gr).NYHA class
As mentioned above, the proportion of patients in each
NYHA class was considered in order to capture the
QoL of HF patients. In the base case analysis, the distri-
bution of patients in each NYHA class was estimated
by applying a generalized ordered logistic regression model
(a proportional odds model) on the SHIFT data. The re-
gression model was designed to predict a time adjusted
NYHA distribution for each treatment arm, separately. Be-
cause of the lack of any evidence to predict the distribution
of patients by NYHA class beyond the SHIFT trial period,
we assumed that the proportions remained fixed after the
trial period. This proportion was set equal to that observed
in the trial at 29 months (LoCF). This approach was con-
sidered more conservative than the extrapolation of SHIFT
data using the ordered logistic regression [11].














Drug costs per month price bulletin issued by the Greek
Ministry of Health [15], law









Intensive Care Unit €200
Cardiac Units €110





HF: Heart Failure; ECG: electrocardiographic changes; NYHA: New York
Heart Association.
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As with the NYHA class, the hospitalization rates related
to HF, other CV causes and all causes for both arms under
study were considered in the model to capture the appro-
priate resource use and the impact on patient’s QoL.
These rates were estimated through Poisson regression
models applied on the SHIFT data. In the base case ana-
lysis, the all-cause hospital admissions were considered.
The treatment effect of ivabradine on the rate of admis-
sions to hospital was estimated using a rate ratio of 0.83
derived from the Poisson regression model. The treatment
effect was modeled on the all-cause admission because
CV and HF admissions were assumed to be implicitly cap-
tured in all-cause admission. Admission to hospital after
the trial was modeled to be equivalent to the within-trial
period and assumed to occur at a constant rate through-
out the model irrespective of the ageing population [11].
Hospitalization length of stay and type of ward
The length of stay (LoS) associated with hospital admis-
sion was estimated using external data based on experts
clinical advice. The average LoS was varied according to
diagnosis on hospital admission (i.e. HF, other CV diagno-
sis and non-CV diagnosis). In the base case model, an
average LoS of 5 days for all-cause hospitalizations were
applied according to data obtained from ministry of
health. The average LoS for HF and other CV diagnosis
was set at 7 and 4 days, respectively, based on local ex-
pert’s advice. Moreover, the experts reported that only
30% of patients with HF spend 3 days in intensive care
units (ICUs) and the remaining 4 days in cardiac units,
while 70% of patients are hospitalized only in cardiac units.
Utilities
Utility values describe the health-related QoL associated
with different health states on a scale of zero to one, where
zero is equivalent to death and one represents best im-
aginable health. Due to lack of local utility values for pa-
tients with HF, the utility values taken from SHIFT-PRO
study in which health-related QoL was captured with EQ-
5D questionnaire were considered in the model (Table 2).
EQ-5D scores were derived using UK population tariff
values [13]. A mixed regression model (designed for longi-
tudinal datasets with repeated observations within respon-
dents) was used to analyze SHIFT EQ-5D scores. The
clinical variables considered to potentially predict patient
QoL were consistent with those considered in the CV and
hospitalization risk equations plus two additional time-
varying variables – hospitalization within a 60 day time
interval (EQ-5D visit date ±30 days) and NYHA class [11].
Costing methods
The present economic evaluation was conducted by the
third-party-payer perspective and as such only healthcare costs reimbursed by the payer were considered in
the analysis. Any other cost, such as the costs related to
the central Government budget to cover personnel salaries
or patients copayments, was not considered. In particular,
hospitalization, medication and HF management costs
were considered in the model. All costs (in €) reflect the
year 2013.
To estimate the total hospitalization cost, the cost per
day for each ward type (i.e. intensive care unit (ICU), gen-
eral medical, cardiac and rehabilitation) was multiplied by
the LoS and the hospitalization rate (described above).
The LoS in each ward type as well as the probability of be-
ing hospitalized to a cardiac unit or ICU was obtained
from local experts. Reimbursement unit costs for bed-day
were obtained from the Diagnostic Related Groups
(DRGs) tariffs issued by the Greek Ministry of Health [14].
The total monthly cost of ivabradine has been estimated
by considering the proportion of patients using 2.5 mg
(10%), 5 mg (70%) and 7.5 mg (20%) in Greece (based on
experts advice) and the current price of ivabradine as it
was obtained from the latest (February 2013) price bulletin
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price of 2.5 mg was assumed to reflect a half dose of
the 5 mg cost, and it is consistent with clinical practice
(i.e. the scored tablets may be halved).
The total monthly cost of SoC has been modeled using
the overall proportions of patients using each SoC ther-
apy based on local experts opinion, the mean daily dose
for each drug as it was reported by local experts and the
relevant drug prices (calculated as the cost per mg)
(Additional file 1, Table 2). Note that the proportions
and daily doses reported by the local experts where in
line with those taken by patients in SHIFT study. In case
that more than one drug was reported from the experts
for a particular SoC therapy group, the weighted cost was
considered in the model (Additional file 2). All drug prices
were obtained from the latest (February 2013) price
bulletin issued by the Greek Ministry of Health [15].
The analysis was undertaken from a payer perspective,
hence drug cost was based on the retail product price
minus the patient copayment (i.e. reimbursed cost). More-
over, cost is net of two different rebates paid by manufac-
turers (law 4052/2012, Government Gazette). In particular,
a rebate of 9% on the ex factory price is applied as a return
for products to be included into the positive list (i.e. a list
of reimbursed products). Additionally, a volume rebate,
ranging from 0 to 8%, is also applied on the ex factory price
based on the quarterly sales of each product. In the present
analysis a 5% is assumed based on a realistic assumption
about possible sales.
An additional one-off cost was also included for ivab-
radine therapy titration. Based on local experts advice,
dosage titration, in Greece, takes place in a routine visit
at the outpatient department of hospital as soon as an
ECG has been undertaken. However, social security funds
do not reimburse the outpatient visit and as a resultthe
dosage titration cost for ivabradine group was considered
to be equal to the cost of ECG as it was obtained from the
Government Gazette (FEK B’ 3054/2012).
The other modeled resource use for SoC included the
on-going HF management (physician visits, outpatient
procedures, tests). The number of visits, the laboratory
tests (blood and biochemical tests) and cardiological tests
(e.g. echo, MRI etc.) required were retrieved from local ex-
perts. The health care utilization and costs for managing
HF were obtained from Government Gazette [16] and
local experts (Table 2).
Data analysis
The base case approach and data were used to get mean
estimates of life time costs, life years (LYs) and quality-
adjusted life years (QALYs) for each comparator. When
new options like ivabradine are more effective (i.e. higher
QALY) and less costly than comparators, they are consid-
ered as “dominant” treatments. In cases where new optionsare less effective and more costly they are considered as
“dominated” by the alternatives. In cases where they are
associated with higher QALY and higher cost they are
considered as cost-effective only when the incremental
cost-effectiveness ratio (ICER) is lower than a specific
predetermined threshold [17-19]. For a treatment to be
considered cost-effective a threshold of €36,000 per
QALY was used in the current analysis. This is based
on the WHO guidelines that states that a treatment
should be considered cost-effective if the ICER is be-
tween 1 or 3 times the gross domestic product (GDP)
per capita of that country and a treatment is considered
highly cost effective at less than 1 times the GDP per
capita [20]. The GDP per capita in Greece was estimated
at €18,000 taken from the IMF estimation of GDP per
capita using current prices [21].
The majority of input data used in the current model
are subjected to variation. Therefore, a probabilistic sen-
sitivity analysis (PSA) was conducted to quantify uncer-
tainty. Multivariate regression functions generated using
SHIFT individual patient data have been entered in the
model along with a Cholesky decomposition to account
for correlated parameters. Monte Carlo simulation has
been used to generate the resulting joint distributions of
total costs and QALYs in the model [22]. The model
outputs have also been expressed in terms of ‘decision
uncertainty’ using cost-effectiveness acceptability curves
(CEACs) which show the probability of each therapy be-
ing cost-effective given a particular threshold value for
cost-effectiveness [23].
Deterministic sensitivity analysis was performed to iden-
tify the parameters and structural assumptions to which the
model was most sensitive. The upper and lower bounds of
parameters were defined by 95% CIs where possible or
plausible variation around the base case values.
Subgroup analyses have been performed for subgroup
populations identified from the clinical study protocol.
These included age (< or ≥75 years old); HF duration
(categorized by quartile cut points); NYHA class; Left
Ventricular Ejection Fraction (categorized by quartile cut
points); prior ischaemia; prior diabetes and β-blocker use.




In the base case analysis, the Markov model revealed
that the discounted survival was higher in ivabradine
plus SoC arm compared to the SoC alone by 0.25 LYs,
while the corresponding discounted QALYs were increased
by 0.28 QALYs.
Moreover, it was found that ivabradine plus SoC was
the most costly treatment regimen versus SoC alone, in
the lifetime horizon (€8,665 versus €5,873, respectively).
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costs account for 61% and 40% of total costs in ivabra-
dine plus SoC and SoC alone, respectively. Following
drug acquisition cost, hospitalization cost accounts for
21% and 30% of the total costs of ivabradine and SoC,
respectively. Finally, follow up costs made up approxi-
mately 30% of the total cost for SoC and 17% for ivab-
radine. Under the base case assumptions, incremental
analysis showed that ivabradine plus SoC was more effect-
ive and more costly than SoC alone, resulting in an ICER
equal to €9,986 per QALY gained indicating that ivabra-
dine plus SoC was a cost-effective alternative (Table 3).
One way sensitivity analysis
Parameter sensitivity analysis
The results of the sensitivity analysis conducted on par-
ameter estimates are reported in the Tornado diagram
featured in Figure 2. It should be noted that the Tornado
diagram has been estimated by applying average covari-
ate values into the risk equations for simplicity (base case
ICER estimate derived using this method €9,196 – ap-
proximately €790 less than the base case ICER estimate -
€9,986 - which was derived by applying individual patient
profiles into the risk equations one at a time). The results
of sensitivity analysis indicated that the ICER was likely to
remain below the threshold of €36,000 per QALY gained
in all scenarios, with the exception of the ivabradine HR
for CV mortality where the ICER exceeded €36,000 when
the HR was set at the upper limit of its 95% confidence
interval. The rest of findings of this analysis suggested a
robustness of results to clinically plausible changes in



















QALYs 4.27 3.99 0.28
LYs 5.86 5.61 0.25
Incremental
analysis
ICER per QALY (€) 9,986
ICER per LY (€) 11,002
ICER: incremental-cost-effectiveness ratio; LY: life-year; QALY: quality-adjusted-
life-year.Structural sensitivity analysis
The results of the structural sensitivity analysis are re-
ported in Table 4. The structural scenario analyses indi-
cate that assumptions have generally been conservative
with respect to the ICER. The use of alternative paramet-
ric distributions (exponential and Weibull) for CV mortal-
ity estimation also both resulted in a more favorable ICER
estimate, while the use of Kaplan Meier data of SHIFT
study to estimate CV mortality resulted in a higher ICER
still below the threshold of €36,000 per QALY gained.
Moreover, structural sensitivity analysis showed that when
the treatment effect of ivabradine was modeled only on
HF mortality, with other CV death modeled as equivalent
to SoC, a more favorable ICER estimate was achieved
(€7,903/QALY gained). Additionally, the results were in-
sensitive to the consideration of titration visit cost and ECG
cost in the model as well as to changes in utility estimates
to other data source (SHIFT predicted versus external
literature) or inclusion of an age-adjustment (higher
utility loss as the modeled cohort aged).
Subgroup analyses
The ICER values have been estimated for a series of sub-
group populations. These subgroup populations were
designed with reference to the clinical trial protocol and
previous SHIFT study populations. The subgroup ana-
lyses indicated that the use of ivabradine plus SoC seems
to be more cost-effective alternative over SoC alone among
patients with more severe heart failure (NYHA class III
and IV), as the ICER becomes lower when the severity
of heart failure increases. The results of subgroup ana-
lyses are presented in Table 5. It should be noted that
ivabradine plus SoC remains a cost effective alternative
in all subgroups.
Probabilistic sensitivity analysis
In the base case analysis, probabilistic analysis confirms
the deterministic results. In particular, the analysis showed
that ivabradine plus SoC is the more cost-effective
comparator (assuming a willingness to pay threshold of
€36,000) for the majority of the run. The probabilistic
sensitivity analysis showed that the likelihood of Ivabra-
dine plus SoC being cost-effective at a willingness-to-
pay threshold of €36,000/QALY was found to be 95%
compared with SoC alone. The CEAC confirms that a
willingness-to-pay threshold of €36,000 ivabradine plus
SoC was the regimen of choice (Figure 3).
Discussion
In the present study, a Markov modeling approach was
used to evaluate the cost-effectiveness of ivabradine in a
lifetime horizon for CHF patients with a baseline heart
rate ≥ 75 b.p.m., compared with current standard of care,
in Greece. The analysis revealed that ivabradine plus SoC
Figure 2 Tornado diagram: results from one way sensitivity analysis.
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to SoC, with an ICER well below the threshold of €36,000
per QALY gained, indicating that ivabradine is a cost-
effective alternative for the management of CHF in
Greece.
Our results are consistent with those submitted to NICE,
in which ivabradine plus SoC was found to be associated
with an increased cost of £8,498 per QALY gained com-
pared with SoC. The ICER was sensitive to changes in the
treatment effects of ivabradine at the upper bound 95%
confidence interval for CV mortality (HR: 0.80-1.03). How-
ever, the risk equations were developed using data from
the total SHIFT population (heart rate ≥70 bpm). There-
fore, this scenario analysis overestimates the upper bound
hazard ratio and ICER estimate for the licensed indication
(heart rate ≥75 bpm) [11].
Although the methodology adopted followed the stand-
ard recommendations and various sensitivity analyses wereTable 4 Summary of structural sensitivity analysis
Parameter
Treatment effect: HF only endpoints
CV: mortality Kaplan Meier vs Gompertz
Ivabradine treatment duration: 5 years vs lifelong
NYHA extrapolation: LoCF vs Assumption based
QoL weights: Exclude age adjustment vs include age adjustment
CV mortality: Weibull vs Gompertz
QoL weights: SHIFT predicted vs external literature
NYHA extrapolation: LoCF vs SHIFT predicted
CV mortality: exponential vs gompertz
Titration visit and ECG costs excluded vs included
CV: cardiovascular; QoL: Quality of Life; ICER: incremental cost effectiveness ratio; H
Association; LoCF: Last observation carried forward.conducted to fully explore uncertainty, the analysis cannot
substitute for real-life direct comparisons amongst the
alternative treatments. Hence, post-launch observational
studies are needed to verify the conclusions obtained from
analyses such as the present. A more complete analysis from
a broader (societal) perspective may also be worthwhile.
True health care and patient direct and indirect costs
are higher than those considered in the present analysis,
and therefore the cost-effectiveness of a new therapy may
be more favourable from a societal perspective. Moreover,
in the present analysis it was assumed that the clinical
outcomes obtained from the SHIFT trial were applic-
able to the Greek health care setting. The use of data
derived from clinical trials may be questionable, however
given the lack of locally generated data, this was the only
relevant source for clinical data; one may argue that
pivotal trials are almost universally used to build models











F: Heart Failure; ECG: electrocardiographic changes; NYHA: New York Heart
Table 5 Results from subgroup analyses















All patients (HR≥ 75 b.p.m.) 5,873 3.99 8,665 4.27 2,792 0.25 0.28 11,002 9,986
Age < 75 years 6,033 4.14 8,932 4.43 2,899 0.27 0.29 10,897 9,909
Age≥ 75 years 4,350 2.54 6,123 2.69 1,772 0.14 0.16 12,944 11,355
NYHA II 6,358 4.55 9,498 4.84 3,140 0.24 0.28 12,935 11,112
NYHA III 5,528 3.55 8,059 3.83 2,531 0.27 0.28 9,542 9,044
NYHA IV 3,383 1.79 4,726 2.00 1,343 0.22 0.21 6,018 6,445
HF duration <0.6 years 6,683 5.02 10,063 5.35 3,379 0.28 0.33 12,085 10,287
HF duration ≥0.6 < 2 years 5,881 4.10 8,752 4.39 2,871 0.26 0.29 10,919 9,883
HF duration ≥2 < 4.8 years 5,489 3.66 8,138 3.92 2,648 0.24 0.26 10,916 10,168
HF duration ≥4.8 years 5,466 3.20 7,755 3.44 2,290 0.23 0.24 9,931 9,527
No beta blocker 5,144 3.08 7,384 3.39 2,240 0.31 0.31 7,239 7,267
Beta blocker < half target dose 5,481 3.60 7,992 3.87 2,511 0.25 0.27 9,942 9,250
Beta blocker = > half target dose < target dose 6,338 4.45 9,438 4.73 3,100 0.24 0.28 12,794 11,115
Beta blocker = > target dose 6,440 4.64 9,684 4.92 3,244 0.24 0.28 13,602 11,619
LVEF < 26% 5,407 3.31 7,709 3.60 2,302 0.28 0.29 8,356 8,072
LVEF ≥26% < 30% 5,483 3.66 8,052 3.94 2,569 0.25 0.27 10,163 9,440
LVEF ≥30 < 33% 5,993 4.19 8,947 4.47 2,955 0.26 0.28 11,558 10,400
LVEF≥ 33% 6,443 4.64 9,688 4.92 3,245 0.23 0.27 13,977 11,807
Non-diabetic 5,746 4.04 8,577 4.32 2,831 0.25 0.28 11,210 10,112
Diabetic 6,150 3.86 8,859 4.14 2,709 0.26 0.28 10,556 9,710
No prior CAD 5,839 4.20 8,719 4.52 2,880 0.29 0.32 9,907 9,051
Prior CAD 5,887 3.90 8,643 4.16 2,756 0.24 0.26 11,549 10,448
HR: Heart rate; CAD: coronary artery disease; HF: Heart Failure; LY: life Years; QALY: Quality-adjusted-life year; NYHA: New York Heart Association; LVEF: Left
Ventricular Ejection Fraction.
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http://www.biomedcentral.com/1472-6963/14/631only two local experts and not an expert panel was used
to obtain local resource utilization and validate some
of the assumptions considered in the model. This fact
might raise concerns about the subjectivity of model
inputs and leave space for challenging the study re-
sults. Nonetheless, he is a well-known cardiologist withFigure 3 The acceptability curve for lifetime analysis.extensive clinical experience on management of CHF, in
Greece. Finally, it should be noted that the results have to
be considered in the strict Greek setting and on the basis
of the present time resource and drug prices. If any of the
underlying parameters change, so may the results and the
conclusions of the analysis.
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http://www.biomedcentral.com/1472-6963/14/631Conclusions
We can conclude that the use of Ivabradine plus SoC
therapy may be regarded as a cost effective alternative
when compared with SoCpy alone.
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